Long Shortz with Island Pharmaceuticals: Could this be the answer to dengue fever?

Fraser Palamara speaks Island Pharmaceuticals (ASX:ILA) CEO and managing director Dr David Foster for an update on the company’s Phase 2a/b PROTECT trial on its lead candidate, ISLA-101.

Island is aiming to treat dengue fever using ISLA-101, with results from the Phase 2a/b trial expected next month.

This video was developed in collaboration with Island Pharmaceuticals.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.